Travere targets $3B FILSPARI sales by 2033 as patent terms extend into 2037

Travere Therapeutics Q3 2026 earnings: FILSPARI sales topped $200M, patent runway extended to 2037, and Q4 headwinds loom.

CryptoAlerta — análise de criptomoedas e mercado em tempo real